Abstract
We conducted a serosurvey in 2020, amongst 149 adult migrants living in the United Kingdom, to determine seroprotection rates for measles, varicella zoster, and rubella. Findings suggest a gap in seroprotection against measles (89.3%). Younger migrants and those from Europe and Central Asia may be more susceptible; self-reported vaccine/disease status is a poor predictor of seroprotection. Understanding factors associated with seroprotection among migrants is critical for informing the delivery of SARS-CoV-2 vaccine.
Competing Interest Statement
MP reports grants and personal fees from Gilead Sciences and personal fees from QIAGEN, outside the submitted work.
Funding Statement
This project was funded by the NIHR East Midlands CRN. CAM is a National Institute of Health Research (NIHR) Academic Clinical Fellow. MP is supported by a NIHR Development and Skills Enhancement Award and acknowledges support and funding from UKRI/MRC (MR/V027549/1), NIHR Leicester BRC and the NIHR ARC East Midlands. SH is funded by the NIHR (NIHR Advanced Fellowship NIHR300072), the Academy of Medical Sciences (SBF005\1111), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID/ESGITM Research Grant). The funders had no role in design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was received from London - Fulham Research Ethics Committee (reference number 19/LO/1846).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint first authors
Data Availability
Data requests can be made to the Chief Investigator and will be considered in conjunction with the Sponsor and Caldicott guardian.
